TransMedics Group, Inc. (NASDAQ:TMDX) Receives $102.00 Average Target Price from Analysts

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report) has received an average rating of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $102.00.

A number of research analysts have weighed in on the stock. Morgan Stanley lifted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Piper Sandler began coverage on shares of TransMedics Group in a report on Thursday, March 28th. They set an “overweight” rating and a $95.00 target price on the stock. JPMorgan Chase & Co. increased their price target on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Finally, Oppenheimer boosted their price objective on TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th.

Get Our Latest Report on TMDX

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Tamer I. Khayal sold 2,330 shares of TransMedics Group stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total value of $209,909.70. Following the sale, the insider now owns 14,375 shares in the company, valued at $1,295,043.75. The disclosure for this sale can be found here. In the last three months, insiders sold 119,408 shares of company stock valued at $10,182,881. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in shares of TransMedics Group by 42.5% in the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company’s stock valued at $258,139,000 after purchasing an additional 1,407,171 shares in the last quarter. Eventide Asset Management LLC lifted its holdings in TransMedics Group by 1,271.7% during the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock worth $50,663,000 after buying an additional 857,895 shares during the last quarter. Mackenzie Financial Corp acquired a new position in shares of TransMedics Group in the 4th quarter worth approximately $35,804,000. Wasatch Advisors LP bought a new stake in shares of TransMedics Group in the 1st quarter valued at approximately $32,162,000. Finally, Summit Partners Public Asset Management LLC raised its position in shares of TransMedics Group by 71.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company’s stock valued at $59,083,000 after acquiring an additional 400,255 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Trading Down 3.5 %

Shares of TMDX opened at $84.16 on Thursday. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $99.63. The firm has a market capitalization of $2.75 billion, a P/E ratio of -109.30 and a beta of 1.99. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The stock’s fifty day simple moving average is $82.88 and its 200 day simple moving average is $73.35.

TransMedics Group (NASDAQ:TMDXGet Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The company had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. During the same period last year, the business posted ($0.21) EPS. The company’s quarterly revenue was up 158.6% compared to the same quarter last year. On average, equities research analysts forecast that TransMedics Group will post -0.14 earnings per share for the current year.

TransMedics Group Company Profile

(Get Free Report

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Recommended Stories

Analyst Recommendations for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.